omalizumab + salmeterol + ticlosone

This is a combination drug consisting of three active ingredients: - **Omalizumab** is a monoclonal antibody that binds to immunoglobulin E (IgE), preventing it from attaching to mast cells and basophils, thereby reducing allergic inflammation. It is primarily used as an add-on therapy for moderate-to-severe persistent allergic asthma and chronic spontaneous urticaria. - **Salmeterol** is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle, leading to bronchodilation. It is commonly used in the management of asthma and chronic obstructive pulmonary disease (COPD). - **Ticlosone** appears to be a misspelling or rare synonym for fluticasone or another inhaled corticosteroid (ICS). In the context provided, it likely refers to an inhaled corticosteroid similar in function to fluticasone, which reduces airway inflammation. The combination of these agents targets multiple pathways involved in asthma pathophysiology—omalizumab addresses IgE-mediated allergic responses; salmeterol provides sustained bronchodilation; ticlosone/fluticasone reduces airway inflammation. This multi-modal approach may be considered for patients with severe or difficult-to-control asthma who have not responded adequately to standard therapies[6].

Other names

omalizumab and salmeterol and ticlosone